TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

Phase 2positiveTEV-408Positive

AI Analysis

Summary

Teva Pharmaceutical's TEV-408 met its primary goal in a Phase IIa study for celiac disease. The positive trial result demonstrates progress in the company's pipeline for this indication.

Clinical Trial Data

Phase

IIa

Primary Endpoint

Met

Outcome Details

Met primary goal in Phase IIa study

Importance:6/10

Sentiment:

0.70

celiac diseasephase 2 datatevaclinical trial

Related Companies

$TEVJF

Read the original article

Published by yahoo_finance on September 3, 2026 3:23 PM

Read Original